Bumetanide detailed information

Bumetanide detailed information

Clinical data
Pregnancy category	AU: B3 US: C (Risk not ruled out)
Routes of administration	oral
ATC code	C03CA02 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	almost complete
Protein binding	97%
Metabolism	hepatic
Elimination half-life	60-90 minutes
Excretion	renal
Identifiers
IUPAC name 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
CAS Number	28395-03-1
PubChem CID	2471
DrugBank	APRD00294
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C17H20N2O5S
Molar mass	364.417 g/mol
3D model (JSmol)	Interactive image
SMILES CCCCNc1cc(cc(c1Oc2ccccc2)S(N)(=O)=O)C(O)=O

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

For patient information, click here

Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. It is marketed by Hoffmann-La Roche with the brand name Bumex. The main difference between the two substances is in bioavailability. Furosemide is incompletely absorbed in the intestine (40%), and there is substantial inter- and intraindividual differences in bioavailability (range 10-90%). Bumetanide is completely absorbed (80%), and the absorption is not altered when it is taken with food. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect.

Bumetanide is 40 times more potent than furosemide (for patients with normal renal function).

External links

• Bumex (manufacturer's website)
• Bumetanide (patient information)